Vivos Therapeutics (NASDAQ:VVOS) stock was up 6% in premarket trading Tuesday after the company said its CARE medical devices for the treatment of sleep apnea have been approved for reimbursement ...

Current obstructive sleep apnea (OSA) diagnosis methods, although often effective, all require the patient to be asleep ...

"Dry throat tissues can increase snoring, so drinking enough water throughout the day should help combat this," he recommends ...

the risk that some patients may not achieve the desired results from using Vivos’ products, (iii) risks associated with regulatory scrutiny of and adverse publicity in the sleep apnea treatment ...

Vivos announces immediate expansion of its new alliance model into two additional Colorado locations as initial reports show sleep apnea patients prefer Vivos CARE treatment for OSA nearly 2 to 1 ...

such as lowering Apnea Hypopnea Index scores. Vivos also markets and distributes SleepImage diagnostic technology under its VivoScore program for home sleep testing in adults and children.

People with obstructive sleep apnea have an increased risk of Parkinson's disease, but if started early enough, continuous ...

Vivos announces immediate expansion of its new alliance model into two additional Colorado locations as initial reports show sleep apnea patients prefer Vivos CARE treatment for OSA nearly 2 to 1 ...

Inc. (“Vivos” or the“Company”) (NASDAQ: VVOS), a leader in novel, non-invasive obstructive sleep apnea (OSA) treatments, today announced several significant milestone achievements in its ...